The effect of treatment by biological agents on quality of life and psychological outcomes in patients with Crohn's disease

This prospective study aimed to evaluate changes in disease-specific and general health-related quality of life, fatigue, depression, and anxiety among adults with Crohn's disease before and after at least six months of treatment with biological agents. A total of 97 adult individuals with CD were prospectively recruited between May 2024 and August 2025. These participants underwent treatment with biological agents, which included infliximab, adalimumab, ustekinumab, or vedolizumab. Standardized measures for HRQoL and psychological outcomes were gathered. To evaluate these outcomes, a variety of tools were utilized, including the Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Symptom Severity (CSS), the 36-item Short Form Survey (SF-36), EuroQol 5-Dimension 5-Level (EQ-5D-5L), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9). These assessments were conducted both before treatment and after at least six months of therapy. Statistical analyses employed paired sample t-tests and non-parametric methods, with statistical significance determined at P < 0.05. The cohort had a mean age of 26.34 years, predominantly male (81.44%), and mainly presented with mild disease (67.01%). Significant improvements were observed in disease-specific HRQoL, with the IBDQ total score increasing from 95.36 ± 13.81 pre-treatment to 122.80 ± 17.80 post-treatment (P < 0.001). Disease severity, as measured by the CSS, decreased significantly from 47.38 ± 5.84 to 38.21 ± 6.67 (P < 0.001). General HRQoL also showed substantial improvement, with SF-36 PCS and MCS scores increasing by 5.00 points (P < 0.001 for both), and the EQ-5D-5L VAS score improving by 11.33 points (P < 0.001). Fatigue, measured by FACIT-F, improved significantly by 9.18 points (P < 0.001). Psychological outcomes also showed notable improvement, with the PHQ-9 score decreasing from 14.28 ± 3.66 to 6.32 ± 4.39 (P < 0.001) and the GAD-7 score decreasing from 12.20 ± 3.15 to 7.22 ± 3.54 (P < 0.001). Biological therapy in individuals with CD was associated with improvements in disease-specific and general HRQoL and reductions in symptom severity, fatigue, depression, and anxiety. These findings support the value of incorporating patient-reported quality-of-life and psychological assessments into biologic-treatment follow-up and comprehensive CD care.

Authors

Institutions

Publication Details

Journal
International Journal of Colorectal Disease
Published
2026-11-20
DOI
https://doi.org/10.1007/s00384-026-05271-y
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The effect of treatment by biological agents on quality of life and psychological outcomes in patients with Crohn's disease

Ning Ding, 周燕丰, 李擎虎, Xiaobing Fu et al.
International Journal of Colorectal Disease
Inflammatory Bowel Disease
article

The effect of treatment by biological agents on quality of life and psychological outcomes in patients with Crohn's disease

Ning Ding, 周燕丰, 李擎虎, Xiaobing Fu, Tianshu Peng, Xianli Liu, Chenxin Li
article en

Abstract

This prospective study aimed to evaluate changes in disease-specific and general health-related quality of life, fatigue, depression, and anxiety among adults with Crohn's disease before and after at least six months of treatment with biological agents. A total of 97 adult individuals with CD were prospectively recruited between May 2024 and August 2025. These participants underwent treatment with biological agents, which included infliximab, adalimumab, ustekinumab, or vedolizumab. Standardized measures for HRQoL and psychological outcomes were gathered. To evaluate these outcomes, a variety of tools were utilized, including the Inflammatory Bowel Disease Questionnaire (IBDQ), Crohn's Symptom Severity (CSS), the 36-item Short Form Survey (SF-36), EuroQol 5-Dimension 5-Level (EQ-5D-5L), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9). These assessments were conducted both before treatment and after at least six months of therapy. Statistical analyses employed paired sample t-tests and non-parametric methods, with statistical significance determined at P < 0.05. The cohort had a mean age of 26.34 years, predominantly male (81.44%), and mainly presented with mild disease (67.01%). Significant improvements were observed in disease-specific HRQoL, with the IBDQ total score increasing from 95.36 ± 13.81 pre-treatment to 122.80 ± 17.80 post-treatment (P < 0.001). Disease severity, as measured by the CSS, decreased significantly from 47.38 ± 5.84 to 38.21 ± 6.67 (P < 0.001). General HRQoL also showed substantial improvement, with SF-36 PCS and MCS scores increasing by 5.00 points (P < 0.001 for both), and the EQ-5D-5L VAS score improving by 11.33 points (P < 0.001). Fatigue, measured by FACIT-F, improved significantly by 9.18 points (P < 0.001). Psychological outcomes also showed notable improvement, with the PHQ-9 score decreasing from 14.28 ± 3.66 to 6.32 ± 4.39 (P < 0.001) and the GAD-7 score decreasing from 12.20 ± 3.15 to 7.22 ± 3.54 (P < 0.001). Biological therapy in individuals with CD was associated with improvements in disease-specific and general HRQoL and reductions in symptom severity, fatigue, depression, and anxiety. These findings support the value of incorporating patient-reported quality-of-life and psychological assessments into biologic-treatment follow-up and comprehensive CD care.

International Journal of Colorectal Disease
Hunan University of Traditional Chinese Medicine (CN), Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine (CN)
Good health and well-being
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon